We evaluated the activity of rezafungin and comparators using Clinical and Laboratory Standards Institute 37 (CLSI) broth microdilution methods against worldwide collection of 2,205 invasive fungal isolates 38 recovered from [2016][2017][2018]. Candida spp. (1,904 isolates; 6 species), Cryptococcus neoformans (73), 39 Aspergillus fumigatus (183) and Aspergillus flavus (45) isolates were susceptibility (S) tested for 40 rezafungin as well as the comparators caspofungin, anidulafungin, micafungin, and azoles. Interpretive 41 criteria were applied following CLSI published clinical breakpoints (CBP) and epidemiological cutoff 42 values (ECV). Isolates displaying non-WT echinocandin MIC values were sequenced for fks hot spot (HS) 43 mutations. Rezafungin inhibited 99.8% of Candida albicans isolates (MIC 50/90 , 0.03/0.06 µg/mL), 95.7% of 44 Candida glabrata (MIC 50/90 , 0.06/0.12 µg/mL), 97.4% of Candida tropicalis (MIC 50/90 , 0.03/0.06 µg/mL), 45 100.0% of Candida krusei (MIC 50/90 , 0.03/0.06 µg/mL), and 100.0% of Candida dubliniensis (MIC 50/90 , 46 0.06/0.12 µg/mL) at ≤0.12 µg/m. All (329/329 [100.0%]) Candida parapsilosis isolates (MIC 50/90 ,1/2 47 µg/mL) were inhibited by rezafungin at ≤4 µg/mL. Fluconazole resistance was detected among 8.6% of C. 48 glabrata, 12.5% of C. parapsilosis, 3.2% of C. dubliniensis, and 2.6% of C. tropicalis. Rezafungin activity 49 against these 6 Candida spp. was similar to the activity of other echinocandins. Detection of fks HS 50 mutation was performed by sequencing echinocandin resistant or non-WT Candida spp. isolates. Good 51 activity was observed by fluconazole and other azoles against Cr. neoformans, whereas echinocandins, 52 including rezafungin, displayed limited activity. Rezafungin displayed similar activity as other 53 echinocandins against A. fumigatus and A. flavus. These in vitro data contribute to accumulating research 54 demonstrating rezafungin potential for preventing and treating invasive fungal infections. 55 56
INTRODUCTION 57 6 displaying echinocandin MIC values greater than the ECV (Table 4 ). The most common substitutions 140 were fks2 HS1 S663P (7 isolates), fks2 HS1 F659_del (2 isolates), fks2 HS1 Y657_del/F658Y (2 141 isolates), and fks1 HS1 S629P (2 isolates). The corresponding rezafungin MIC values ranged from 0.06 142 to 2 µg/mL (82.4% > ECV [0.12 µg/ml]) for all 17 isolates with an fks mutation (Table 4) . Among all C. 143 glabrata isolates from [2016] [2017] [2018] 8 .6% displayed a fluconazole-resistant phenotype. Based on the ECV 144 cutoff published by CLSI, 7.0% and 12.8% of these isolates were categorized as NWT to posaconazole 145 and voriconazole, respectively (39, 40) (Table 3) . High rates of resistance to fluconazole were seen in 146 isolates from EUR (6.0%) and NA (13.2%) ( Table 5 ). Not only was C. glabrata a rare cause of IC in 147 LATAM (Table 1) , it was also less resistant to fluconazole (0.0%) compared to the other monitored 148 regions (Table 5) . 149
Rezafungin inhibited all C. parapsilosis isolates (n = 329) at the ECV of ≤4 µg/mL (Table 2) . Rezafungin 150 activity (MIC 90 , 2 µg/mL) was similar to that observed for micafungin (MIC 90 , 1 µg/mL; 100.0% S) and 151 anidulafungin (MIC 90 , 2 µg/mL; 93.9% S) and was 4-fold lower than caspofungin (MIC 90 , 0.5 µg/mL; 152 100.0% S) (Tables 2 and 3 ). Among C. parapsilosis, a total of 41 isolates (12.5%) were categorized as 153 fluconazole resistant, and 36 of these strains (87.8%) were from European medical centers (24.8% 154 fluconazole resistant) ( Table 5 ). Although C. parapsilosis was common in LATAM (20.2% of Candida 155 isolates, second in rank order; Table 1 ), no fluconazole-resistant strains were detected among 49 isolates 156 tested (Table 5 ). 157 C. tropicalis (n = 196) isolates were largely susceptible to anidulafungin, caspofungin, and micafungin 158 (99.0% S; Table 3 ). Rezafungin (MIC 50/90 , 0.03/0.06 µg/mL) inhibited 97.4% of isolates at the proposed 159 ECV of ≤0.12 µg/mL (Tables 2 and 3 ). Among 7 C. tropicalis isolates categorized as NWT to 160 echinocandin and submitted to fks sequencing, 2 harbored fks1 HS1 mutations leading to amino acid 161 alterations (S645P and F650S; Table 4 ). Both isolates were resistant to anidulafungin (MIC values of 1 162 µg/mL for both), caspofungin (MIC values of >8 and 2 µg/mL), and micafungin (MIC values of 2 and 1 163 µg/mL) and NWT (MIC > ECV, 2 and 1 µg/mL) to rezafungin. The remaining 5 isolates did not contain 164 fks1 mutations and 4 were WT to rezafungin (MIC values ≤0.12 µg/mL). Fluconazole resistance was 165 observed in 5 C. tropicalis isolates (2.6% of total; Table 5 ). No fluconazole-resistant strains were among 166 45 isolates from NA and 5.0% of isolates from APAC were resistant to fluconazole (Table 5) . 167 on February 6, 2020 by guest http://aac.asm.org/ Downloaded from Rezafungin (MIC 50/90 , 0.03/0.06 µg/mL) was active against 77 C. krusei; 100.0% of isolates were inhibited 168 at ≤0.12 µg/mL, the ECV for this species (100.0% WT; Tables 2 and 3 ). These isolates were susceptible 169 to anidulafungin (MIC 50/90 , 0.06/0.12 µg/mL; 100.0% S), micafungin (MIC 50/90 , 0.06/0.12 µg/mL; 100.0% 170 S), and caspofungin (MIC 50/90 , 0.12/0.25 µg/mL; 98.7% S) (Table 3) according to CLSI breakpoint criteria. 171 Four C. krusei isolates were NWT to one or more echinocandin, none of which were shown to possess an 172 fks mutation: all were WT to rezafungin (Table 4 ). Voriconazole was active against 96.1% of C. krusei 173 isolates and all isolates displayed posaconazole WT phenotype (Table 3) (Table 2) . Notably, these values are far below the peak achievable plasma concentrations of 22-202 30 µg/mL at the 400 mg dose (15, 26, 27) and are equivalent to the ECVs established for these 203 species/species groups and the clinically available echinocandins (40, 42, 43) . 204
205
Additional support for these ECVs is found in a recent multicenter study of rezafungin activity against 206
Candida spp. determined using the EUCAST BMD method and both visual and statistical means of 207 determining possible wild type-upper limit (WT-UL) values (28). In the four-laboratory study, WT-UL 208 cutoffs were proposed for C. glabrata (0.125 µg/mL), C. krusei (0.125 µg/mL), and C. parapsilosis (4 209 µg/mL). Although interlaboratory variation precluded proposing cutoffs for C. albicans and C. tropicalis, 210 the WT-UL statistical 97.5% endpoint was 0.063 µg/mL for C. albicans and 0.25 µg/mL for C. tropicalis 211 (28). These values compare favorably with the ECVs generated by the CLSI BMD method in the present 212 study. Although an essential agreement rate (+/-2 dilution steps) of 92.0% for C. albicans and 100.0% for 213 C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei between CLSI and EUCAST methods for 214 rezafungin was observed previously (31), alignment between CLSI and EUCAST susceptibility profiles 215 and breakpoints is yet to be determined, as significant interlaboratory EUCAST MIC variability (likely 216 attributed to nonspecific binding of the drug to plastics) has been identified for rezafungin against a more 217 susceptible collection of Candida spp. (28, 44) . 218 219 As seen in Table 4 , the highest rezafungin MIC values for fks mutant strains of C. albicans and C. 220 glabrata were 0.25 µg/mL and 2 µg/mL, respectively. Both of these mutant MIC values are within the 221 range of concentrations that Bader et al (20) estimated would achieve percent probabilities of PK-PD 222 on February 6, 2020 by guest http://aac.asm.org/ Downloaded from target attainment of 100% through week 6, suggesting that weekly regimens of rezafungin can achieve 223 exposures associated with efficacy against some fks mutant Candida isolates (20). In addition, the same 224 study showed that the mutant prevention concentration, the concentration of drug that would inhibit 225 emerging resistant mutants, for both rezafungin and micafungin was 16 µg/mL (27) . Given that the high 226 plasma drug exposure of rezafungin easily exceeds the mutant prevention concentration for Candida, a 227 possible advantage of rezafungin may be to prevent resistance development in the echinocandin class of 228 antifungal agents (20, 22, 24, 27) . 229 230 Expert panel guidelines from both NA (5) and EUR (12) favor step-down therapy to fluconazole or 231 voriconazole for patients with Candidiasis in specific clinical situations, that is when clinical improvement 232 and clearance of Candida from the bloodstream was achieved by initial echinocandin therapy. In addition, 233 the organism must be susceptible to fluconazole (e.g., C. albicans, C. parapsilosis, and C. tropicalis) or 234 voriconazole (e.g., C. krusei). Unfortunately, antifungal susceptibility testing is still not routinely available 235 in many patient care settings. In these circumstances, clinicians are forced to rely on simple species 236 identification of Candida as a predictor of fluconazole susceptibility (5, 12) . In most instances, isolates of 237 C. albicans, C. parapsilosis, and C. tropicalis are considered to be reliably susceptible to fluconazole (16), 238 whereas C. glabrata and C. krusei are considered to be intrinsically less susceptible or resistant and are 239 suboptimal targets for using fluconazole (5, 12) . This approach may be seriously flawed if fluconazole 240 resistance emerges among the traditionally susceptible species. Concern regarding this approach has 241 been raised by Oxman et al (45) who found that despite the small proportion of C. albicans, C. 242 parapsilosis, and C. tropicalis with resistance/decreased susceptibility to fluconazole, these species 243 comprised 36% of the reduced susceptibility group (including C. glabrata and C. krusei), potentially 244 compromising therapy with resultant clinical failure. These concerns are supported by data from the 245 current survey showing that resistance to fluconazole was 0.4% for C. albicans, 12.5% for C. parapsilosis, 246 and 2.6% for C. tropicalis (Tables 3 and 5 ). In aggregate, these three normally susceptible species 247 accounts for 31% of all fluconazole-resistant isolates. Species identification should be used cautiously as 248 the sole criterion for anti-Candida agent selection (5, 45) . 249 on February 6, 2020 by guest http://aac.asm.org/
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The increased rate of fluconazole resistance among C. parapsilosis (12.5% overall) and C. tropicalis 250 (2.6% overall) in the present study is important as these species are the most commonly isolated non-C. 251 albicans species in LATAM (Table 1) . Although less common than C. glabrata in EUR, the finding of 252 fluconazole resistance in 24.8% of C. parapsilosis isolates exceeds that observed in C. glabrata (6.0%) 253 isolates and is cause for alarm (Table 5) . 254
This survey has some limitations as noted elsewhere (16): the SENTRY Surveillance Program is a 255 sentinel surveillance and not population-based; therefore, we may over/underestimate the activity of the 256 tested agents. In addition, we do not collect data concerning antifungal use or outcomes of therapy. The 257 purpose of SENTRY is to identify trends in antifungal resistance and to document the emergence of new 258 species as well as the activity of new and established agents against key fungal pathogens. The broad 259 geographic distribution, longitudinal nature of the surveillance, and the use of molecular and proteomic 260 identification methods and determination of resistance mechanisms is a strength of the SENTRY 261
Program. 262
In conclusion, we have provided additional in vitro data demonstrating the activity of rezafungin against a 263 collection of largely echinocandin-WT isolates of Candida spp., Cr. neoformans, A. fumigatus, and A. 264 flavus species complex. Given these findings, we suggest that MIC values of ≤0.12 µg/mL (C. 
MATERIALS AND METHODS 280
Organisms. During 2016-2018, 2,205 non-duplicate fungal isolates were prospectively collected from 57 281 medical centers located in North America (723 isolates; 18 sites, 17 USA and 1 Canada), EUR (927 282 isolates; 22 sites, 14 countries), the APAC region (279 isolates; 11 sites, 5 countries) and LATAM (276 283 isolates; 6 sites, 4 countries). Isolates were recovered from the following sources: bloodstream infections 284
(1,460 isolates), pneumonia in hospitalized patients (306), intra-abdominal infections (32), skin and skin 285 structure infections (106), urinary tract infections (35), and other or non-specified body sites (266). 286
Fungal identification methods. Yeast isolates were subcultured and screened using CHROMagar 287
Candida (Becton Dickinson, Sparks, MD) to ensure purity. Matrix-assisted laser desorption ionization-time 288 of flight mass spectrometry (MALDI-TOF MS) was applied for identification of all yeast isolates using the 289 MALDI Biotyper according to the manufacturer's instructions (Bruker Daltonics, Billerica, MA). Isolates 290 that were not identified by proteomic methods were submitted to the described sequencing-based 291 methods (43, 46, 47 Screening for 1,3-β-D-glucan synthase mutations. All Candida spp. isolates that were echinocandin-325 resistant or showed MIC values higher than the ECV for any echinocandin were submitted to whole 326 genome sequencing for detecting mutations in the HS regions of fks1 and fks2 (C. glabrata only) as 327 described previously (43, 48, 50 ≤0.002 a 0.004 a 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 ≤0.002 a 0.004 a 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 
